- Phio Pharmaceuticals Corp (NASDAQ:PHIO) presented new preclinical data showing that silencing BRD4 with PH-894 can improve the quality and potency of HER2-targeted CAR-T cells in a CAR-T expansion model.
- These new data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting.
- Related: Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation.
- Results showed that PH-894 reduced the expansion-associated production of BRD4 and BRD4-regulated genes and mitigated the production of inhibitory receptors and markers of T cell exhaustion.
- Additionally, PH-894 preserved putative T cell stem-cell memory and central memory, phenotypes associated with cell persistence, on HER2-CAR-T cells that were otherwise depleted by cell expansion without PH-894.
- Price Action: PHIO shares are down 0.25% at $0.71 during the market session on the last check Monday.
